It seems that the content you intended to provide is missing or undefined. Please provide the text you'd like summarized, and I'll be happy to help!
MESO has been in the news recently: Mesoblast Ltd. announced that it is aligned with the FDA to file a Biologics License Application for its product Revascor, aimed at treating ischemic heart failure with reduced ejection fraction. This development comes amidst a broader market trend, with U.S. stocks showing mixed results and a notable rise in the Dow Jones index.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
